Cravings in Addiction: Triggers, Urges, and Behavior

Author: Angela Bogdanova · Published: October 19, 2026 · Editorial Policy

Research cluster: Substance Use Disorders and Addiction Recovery · Written by Artificial Sapiens

Craving is a strong desire or urge to use a psychoactive substance. It can appear as an intrusive thought, a felt pull toward alcohol or another drug, a bodily sensation, a vivid anticipation of use, or a sequence of seemingly automatic decisions that bring a person closer to a substance. Craving is clinically important because it connects learned associations, momentary emotional states, motivational processes, and actual opportunities for use. Yet the experience varies substantially: one person feels an unmistakable urge, another notices only restlessness or attention drawn toward a familiar setting, and someone else reports little conscious craving while still following a well-established substance-use routine. Craving is one diagnostic criterion within the broader assessment of substance use disorder, rather than a diagnosis on its own. DSM-5-TR criteria summarized by NCBI Bookshelf.

An addiction craving becomes more intelligible when it is examined as a changing relationship among a person, a learned cue, an expected outcome, and a possible behavior. Environmental reminders can activate substance-related memories. Stress or withdrawal discomfort can increase the immediate value of anticipated relief. Attention and action tendencies can then shift toward obtaining a substance, while available alternatives, safety, goals, treatment, and social context influence whether use follows. The strongest research synthesis available across many substances reports a prospective association between cue and craving indicators and later substance use or recurrence. That relationship is informative about risk, though a statistical association cannot establish that every urge will cause use or that suppressing every craving automatically prevents recurrence. Vafaie and Kober, 2022.

What Craving Means in Addiction Science

A subjective urge within a multidimensional clinical condition

In ordinary language, a craving may describe wanting chocolate or coffee. In clinical addiction science, the focus is a strong desire or urge specifically directed toward using a psychoactive substance, often shaped by past intoxication, relief, habit, expected consequences, and the surrounding context. The urge can be brief, recurring, persistent, powerful, or barely noticeable. Its intensity may change within minutes and across longer phases of abstinence, treatment, and recovery. People may also distinguish wanting an immediate effect from wanting to escape discomfort, calm tension, participate socially, or resume a familiar ritual. Such motives can coexist within the same episode.

Craving is included among the impaired-control criteria for substance use disorders in DSM-5-TR. The complete disorder diagnosis depends on a broader pattern of clinically relevant symptoms over the specified period, with at least two criteria required for most substance-use disorder categories. A person can experience craving without meeting diagnostic threshold, just as a person can satisfy other criteria without endorsing powerful conscious urges. Clinical interviews therefore examine craving alongside control over use, time devoted to use, functional impairment, hazardous situations, health consequences, and the specific substance involved. Hasin and colleagues, 2013.

Craving, liking, expectation, and intention

Researchers distinguish several processes often compressed into the everyday word wanting. Liking refers to the pleasurable impact of an experience. Wanting, in incentive-sensitization theory, denotes a motivational pull assigned to an anticipated reward or related cue. Expectation concerns what a person believes will occur after use, whereas intention concerns an anticipated decision or plan. A person may intensely want a substance while anticipating very little pleasure from it. Another person may expect it to help with social anxiety while reporting moderate urge, and a third may have a clear intention to avoid use in spite of an intense craving. These distinctions explain why asking only whether a substance sounds pleasurable can underestimate motivational risk. Robinson and Berridge, 2025.

Subjective descriptions also differ. Some cravings are sensory, involving imagined taste, smell, smoke, or bodily sensations. Others have a cognitive character, such as recurrent planning, mental bargaining, or selective attention to possible opportunities. Affective cravings are colored by agitation, excitement, boredom, loneliness, or anticipation. Behavioral tendencies may emerge as movement toward a shop, renewed contact with a supplier, or searching a familiar location. These are clinically useful descriptions of an episode; they should not be mistaken for a universal sequence through which every person must pass.

Craving, physical dependence, tolerance, and withdrawal

Physical dependence refers to physiological adaptation that can produce withdrawal symptoms when exposure to a substance is reduced or stopped. Tolerance refers to a diminished effect of a given amount or the need for a greater amount to obtain a comparable effect. Craving is a motivational phenomenon and can occur with or without obvious withdrawal. In turn, someone undergoing withdrawal may primarily experience physical symptoms, distress, or danger without a strong self-reported desire to use. Compulsive substance use concerns persistent or poorly controlled behavior despite consequences, a broader pattern that cannot be inferred from any single craving rating.

The boundaries have immediate clinical implications. A craving for alcohol does not reveal whether a person is at risk of seizures or delirium during alcohol withdrawal; a craving for opioids does not establish the degree of physiological dependence or whether overdose is occurring. Patients taking certain medications as prescribed may develop physical dependence without addiction. Conversely, substance use disorder can involve psychological and behavioral impairment that extends beyond physiological adaptation. Accurate assessment names each phenomenon separately and connects it to substance-specific safety and treatment needs. Koob and Volkow, 2016.

Why Triggers Produce Urges

External cues: places, objects, people, and routines

A trigger is a condition that raises the probability or intensity of a substance-related response in a given person. External triggers may include the sight of alcohol, a smoking area, a particular route home, a phone notification from a previous contact, music associated with use, payday, or a room where use repeatedly occurred. The trigger can be a direct substance cue or a broader setting associated with availability, pleasure, conflict, or relief. With repeated pairings, a neutral object or occasion acquires predictive meaning. The resulting reaction may involve attention, memory, bodily arousal, anticipation, and the subjective experience of wanting.

Triggers are personal and contextual. The same restaurant may be a strong cue for one person and entirely ordinary for another. A person who previously drank after work may respond to late-afternoon fatigue, while someone whose use occurred in social gatherings may experience a stronger response to invitations or reunion events. Context can also change the impact of a cue: a bottle encountered in a controlled research laboratory may produce a different reaction than the same bottle during an emotionally charged evening with available money, familiar companions, and limited support. The NIAAA trigger guide distinguishes external and internal triggers.

Internal cues: affect, thought, memory, and bodily state

Internal triggers include anxiety, anger, sadness, excitement, fatigue, loneliness, remembered pleasure, anticipation of a difficult conversation, or an uncomfortable bodily sensation. A thought can act as a cue when it recalls a prior episode of relief or reward. Craving can also follow positive moods: celebration, self-confidence, or the expectation that a demanding week has ended. It is therefore misleading to equate substance-related urges exclusively with distress or to interpret every craving as evidence that an underlying emotion has been consciously identified.

Internal and external triggers often operate together. A difficult day may elevate tension; passing a familiar store may activate memory; an advertisement may focus attention on the substance; and knowledge that the next morning is free may reduce perceived barriers. A clinician can explore how these elements converge without treating every trigger as a sufficient cause. Distinguishing their order also prevents hindsight bias: after recurrence, people may identify a memorable trigger even when an episode arose from several interacting conditions. Serre and colleagues, 2015.

Conditioning and associative learning

Classical conditioning describes how a previously neutral cue can acquire an association with a biologically or psychologically important event. Repeated exposure to alcohol in a familiar setting, for instance, can link sensory and contextual cues with intoxication, anticipated social effects, or the relief of discomfort. Instrumental learning adds another dimension: actions that produce reinforcing outcomes become more likely to recur when similar opportunities arise. A cue may therefore provoke a subjective urge and activate a learned action sequence, while the reinforcing outcome may involve reward, withdrawal relief, avoidance of distress, or social consequences.

Learning is not a mechanical guarantee that an urge will lead to consumption. The predictive significance of a cue changes as people acquire new experiences, contexts, goals, and response options. The same visual reminder can become less compelling in one environment yet remain powerful in another. Extinction learning in a laboratory may also be context-specific, which helps explain why an apparent reduction in cue response during treatment does not always transfer to complex real-life settings. Associations can persist after long intervals, reappear in high-risk circumstances, or compete with newly learned responses. Robinson and Berridge, 2025.

Social and commercial environments

Substance availability, price, advertising, norms, daily schedules, housing stability, and peer networks alter how often cues occur and which responses are feasible. A person living in a setting with repeated substance offers encounters a different risk environment from someone with stable housing and supportive relationships. Social interactions may serve as reminders of use or as sources of practical assistance and competing rewards. A cue-centered explanation that omits these social conditions risks attributing behavior solely to an individual's inner response when opportunity structures meaningfully affect exposure and choice.

The commercial design of alcohol and nicotine environments is especially relevant because product displays, advertising, celebrations, and retail access are recurring features of ordinary life. Clinicians and researchers should assess these contexts as exposures that interact with learning and social position rather than assuming every person can permanently eliminate them. The scientific question is how cue meaning, exposure frequency, access, and protective circumstances combine to influence the trajectory of use.

How an Urge Becomes Behavior

Attention, salience, and the orientation response

Substance-associated cues may attract attention quickly or repeatedly. The attention response can occur before a person has formed a deliberate plan to use. Some individuals notice the substance more readily in a crowded environment, mentally rehearse obtaining it, or find competing goals harder to sustain during a strong urge. Incentive-sensitization theory proposes that repeated drug exposure can make certain reward-related cues especially motivationally salient, so they come to elicit intense wanting that is partly dissociable from pleasure. The theory has substantial experimental support and ongoing discussion about its scope and interpretation. Robinson and Berridge, 2025.

Dopamine participates in motivational learning and incentive processes, but a craving episode cannot be reduced to a single transmitter, brain region, or measured dopamine value. Human craving includes memory, expectation, attention, affect, internal state, learned habit, decision processes, and interpersonal context. Brain imaging can reveal group-level differences in activation during cue tasks, while individual predictions from an isolated scan remain limited. The evidence supports interacting neural systems and behaviorally observed processes, rather than a direct map from one brain signal to an inevitable act of substance use. Koob and Volkow, 2016.

Positive reinforcement and relief-driven motivation

In early use, anticipation of pleasurable effects or social reinforcement may be prominent. With repeated use and physiological or psychological adaptation, some episodes are increasingly motivated by relief from dysphoria, stress, sleep disturbance, or withdrawal discomfort. Negative reinforcement refers to the strengthening of behavior when it removes or reduces an unpleasant state. These processes can coexist; an individual may anticipate relief and pleasure simultaneously, or the dominant motivation may vary from one episode to another. Neurobiological models integrate reward, stress, habit, and executive-control changes into the clinical course of addiction. Koob and Volkow, 2016.

A person who experiences a sudden urge after conflict may expect a substance to interrupt painful emotion, even when prior use has repeatedly made circumstances worse. The learned expectation can become influential because the anticipated near-term effect receives more weight than delayed consequences. The clinical task is to understand this time-sensitive valuation alongside availability and behavioral history. Treatment does not require assuming that all use serves the same motivational purpose or that every craving can be classified neatly as pleasure seeking versus escape.

Habits, automaticity, and choice

Habit learning allows repeated action sequences to become efficient and less dependent on deliberate evaluation of every step. A route, location, time of day, or social routine may evoke preparation for use even when conscious craving remains low. Repetition also produces opportunities for habit and motivational wanting to interact. A person might first begin a routine automatically and then notice craving after encountering a cue, or feel an intense urge while actively deciding not to follow a well-practiced sequence.

Compulsive use describes persistence despite substantial adverse consequences and difficulty maintaining control. It cannot be established by observing one automatic movement or isolated urge. Behavioral organization remains sensitive, to varying degrees, to changing alternatives, consequences, treatment, and social circumstances. Theories emphasizing habit, incentive motivation, negative reinforcement, or impaired control illuminate different components of behavior; none alone describes every patient or substance. Their complementarity and disagreements are part of the current addiction science literature. Robinson and Berridge, 2025.

Urge, decision, opportunity, and outcome

An urge may precede use when substances are immediately accessible and the anticipated benefits seem compelling. It may also pass without use when the person cannot obtain the substance, engages an alternative activity, receives support, or acts according to a sustained recovery goal. People can experience a recurrence of use after an apparently mild urge, particularly where habits and social opportunities dominate. Therefore the measurable relationship between craving and behavior is probabilistic. Exposure, desire, availability, self-regulation, social support, intoxication, withdrawal, and existing treatment together shape outcomes.

This distinction matters for clinical conversations. Asking whether a person gave in to a craving can obscure the role of opportunity and support. Asking what happened before, during, and after an episode reveals the pattern more fully. A report of strong craving without use may indicate a moment of substantial risk successfully navigated; a report of use with low craving may identify habitual or situational pathways requiring different attention.

What Neuroscience Can and Cannot Explain

Reward, stress, and executive-control systems

Current neuroscience commonly organizes addiction-related mechanisms across interacting systems involved in reward and motivation, negative affect and stress, and executive control. These systems develop and respond to experience over time. Cue-related activation may involve the ventral striatum, amygdala, insula, prefrontal regions, hippocampal learning systems, and other networks, depending on the task and substance. These findings concern probabilistic patterns in groups and experimental conditions; they do not imply that all people with addiction have identical neural alterations. Koob and Volkow, 2016.

Neuroimaging meta-analyses of alcohol cue reactivity provide evidence that substance cues engage motivational and emotional brain systems, while revealing considerable variation in experimental cues and participant characteristics. Interpreting a blood-oxygen-level-dependent signal as an isolated psychological mechanism would overstate what imaging can show. A high activation contrast does not itself measure how much a person wants a substance or determine what they will do outside the scanner. Schacht, Anton, and Myrick, 2013.

Incentive sensitization and wanting without liking

Incentive-sensitization theory emphasizes the capacity of drugs and associated cues to acquire powerful motivational properties. Its especially important claim is that heightened wanting can persist even when the substance has become less pleasurable. The theory helps explain experiences in which someone describes being drawn toward use while intellectually expecting disappointment or harm. It also directs attention to individual vulnerability, prior exposure, the current motivational state, and cue presentation. The contemporary review of the theory explicitly considers competing models and continuing debates over the roles of craving and compulsion. Robinson and Berridge, 2025.

The theory does not establish that one neural mechanism inevitably causes recurrence. Evidence comes from animal experiments, human behavioral studies, neuroimaging, and clinical observations, each with different inferential strengths. Applying a mechanistic theory to an individual clinical case requires the person's substance history, psychiatric and medical status, behavioral patterns, and recovery context.

Interoception and bodily predictions

Interoception concerns perception and interpretation of internal bodily states. Craving may be experienced through heartbeat changes, stomach sensations, tension, restlessness, or a diffuse feeling that something is missing. The insula and other systems involved in internal-state representation have been studied in relation to urges. Bodily signals also overlap with panic, pain, hunger, fatigue, and medication effects. A physical sensation is therefore not diagnostic of craving by itself, and a person can describe craving even without prominent bodily changes.

Anticipatory states may blend expected reward, discomfort, attention, and bodily memory. Clinical evaluation is strengthened when it asks patients to describe exactly what they notice rather than assigning all autonomic arousal to substance seeking. The same symptom may call for immediate medical evaluation when it occurs alongside intoxication, withdrawal, chest pain, confusion, or other danger signs.

What Research Finds About Craving and Subsequent Substance Use

Prospective evidence and its proper interpretation

A 2022 systematic review and meta-analysis pooled 656 statistics from 237 studies, covering 51,788 participants, including 21,216 with confirmed substance use disorders. Across cue exposure, physiological reactivity, cue-induced craving, and self-reported craving indicators, the authors found a significant prospective association with subsequent substance use or recurrence; the pooled odds ratio was 2.05, with a 95% confidence interval of 1.94 to 2.15. The review also reported publication-bias-adjusted estimates that were smaller, including a trim-and-fill odds ratio of 1.31. These figures summarize different measures and study contexts; they are not a prediction that an individual urge doubles a particular person's probability of use. Vafaie and Kober, 2022.

The study's contribution is the consistency of a prospective signal across many designs. Its limits matter equally: much of the literature is observational, craving and cue measures vary, time lags differ, and the meaning of a one-unit change is not constant across measurement scales. A prospective association shows that the indicator preceded the outcome in the recorded period; it does not isolate causal pathways, fully exclude confounding, or determine whether an intervention targeting the indicator will improve long-term functioning. The most responsible clinical inference is that craving deserves assessment as one dynamic component of substance-use risk.

Laboratory cue reactivity versus daily life

A laboratory cue-reactivity task exposes participants to alcohol or drug-associated stimuli while measuring self-report, physiology, attention, or brain activity. This can standardize stimulus presentation and help compare mechanisms. Everyday episodes involve less controlled combinations of availability, obligations, interpersonal events, stress, intoxication, expectations, and social support. An effect observed during a task may therefore differ from the same person's experience in a familiar neighborhood or at home.

Ecological momentary assessment addresses some of this gap by collecting repeated reports in the environments where people live. Participants may record craving, mood, cues, and use multiple times across a day, reducing dependence on distant retrospective memory. A systematic review found strong links between momentary craving and substance use, particularly across tobacco studies, while documenting variation between people and contexts and sparse research on some illegal drugs. Such studies sharpen temporal understanding without eliminating self-report error, missing data, or confounding. Serre and colleagues, 2015.

Craving intensity, frequency, and duration

The highest rated urge on a particular day, the number of episodes, their duration, and their interference with functioning are related but different quantities. One intense urge may pass quickly; moderate cravings may recur throughout the day and repeatedly disrupt attention. Someone may have powerful cue responses during early abstinence and much lower responses later, yet still encounter occasional intense episodes after a long interval. Measurement must specify what is being counted and when.

Craving scores also depend on whether they are recorded at baseline, immediately after an evocative cue, before substance use, during withdrawal, after a medication adjustment, or in a controlled treatment session. Apparent disagreement between studies can reflect different operational definitions. For patients, a single score is most informative when compared with their own previous reports, level of distress, actual behavior, and clinical circumstances rather than treated as an absolute index of addiction severity.

Is craving necessary for relapse?

Craving is a useful risk indicator, but recurrence can occur without strong conscious craving, through established habits, unexpected opportunities, social pressure, intoxication, or decisions that begin before the person recognizes an urge. Conversely, intense cravings may occur during sustained abstinence or reduced use. The relevant unit of explanation is the changing relationship between motivational state, learned behavior, access, goals, and support. The outcome may be one episode of use, a return to a sustained pattern, or continued recovery with significant distress; these events require distinct descriptions.

This distinction also protects patients from interpreting the reappearance of an urge as a personal or treatment failure. Recovery can include ongoing cue sensitivity, and the presence of an urge alone says little about current functioning, adherence, or long-term prognosis. Persistent or escalating craving deserves attention because it may signal a need to reassess care, not because it mechanically forecasts an inevitable outcome.

How Clinicians Assess Cravings

A focused clinical history

Clinicians can ask what the urge feels like, when it occurs, which substance it concerns, whether it appears after identifiable cues, how long it tends to persist, and what behaviors usually follow. They also ask about current use, last use, changes in pattern, withdrawal symptoms, prior overdose, medical conditions, prescribed medications, psychiatric symptoms, and present safety. Craving is interpreted within this clinical history; screening instruments are intended to flag potential concerns, and a diagnosis requires an appropriately trained professional's assessment of the full criteria and differential possibilities.

Examples of useful inquiry include the difference between wanting a particular effect and trying to escape discomfort; whether the urge follows a predictable setting; whether the individual has acted on similar urges recently; and whether access to substances has increased. Clinicians also consider how the person prefers to describe the experience. The language should remain respectful and concrete, with no assumption that the mere disclosure of an urge means unwillingness to recover.

Ratings and validated questionnaires

Single-item visual analog or numeric ratings can describe momentary craving intensity. Multi-item questionnaires may distinguish desire, anticipated relief, intention, and perceived control, or focus on alcohol, smoking, or another substance. Instruments used in research include the Alcohol Urge Questionnaire and Questionnaire of Smoking Urges, among others. Comparability depends on their validation, reference period, setting, language, and target population. A research measure of craving is not a substitute for a substance-use disorder diagnostic interview or an acute-risk assessment. Thaysen-Petersen and colleagues, 2025.

Repeated measurements may reveal clinically meaningful within-person changes, particularly when tied to situational data and actual substance-use outcomes. However, a high score need not mean severe disorder, and a low score cannot establish safety. In a patient with opioid exposure, for example, a low craving rating offers no assurance against overdose risk if respiratory depressants have been used. Measuring subjective urges and evaluating acute toxic states are separate clinical activities.

Ecological momentary assessment and digital logging

Daily-life monitoring can capture rapidly changing exposure and motivation while helping clinicians discuss actual episodes rather than general impressions. In research, mobile prompts can record cue exposure, craving, affect, location categories, and substance use. Practical limitations include privacy, device access, alert fatigue, reactivity to repeated questions, missing entries during high-risk periods, and inconsistent willingness to record stigmatized behavior. Patterns derived from a particular person's data must be interpreted alongside that person's circumstances.

Digital tracking becomes clinically meaningful when it informs an agreed care plan and does not create a false impression of continuous professional monitoring. Consumer apps vary in safeguards, evidence, and data practices. Automated predictions of individual recurrence remain methodologically challenging; their risk scores should not replace clinical judgment or emergency services.

Differential assessment and co-occurring conditions

Restlessness, agitation, insomnia, preoccupation, low mood, intrusive thoughts, and bodily discomfort can accompany craving, withdrawal, anxiety disorders, depressive episodes, pain, medication adverse effects, or another clinical condition. Co-occurrence is common, and symptoms may change when use changes. Differentiation requires history, timing relative to substances, observed signs, functional impact, and appropriate medical evaluation. A single phrase such as 'I need something' is insufficient to establish the clinical source of distress.

Anxiety may increase the urge to use for short-term relief, while use and withdrawal may themselves intensify anxiety. These questions intersect with the separately owned article Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity. Psychotic symptoms arising during stimulant or cannabis exposure raise different urgent diagnostic and safety questions, examined in Substance-Induced Psychosis: Causes, Symptoms, and Treatment.

Substance-Specific Patterns of Craving

Alcohol: cues, expectations, and changing drinking goals

Alcohol cravings often involve contextual cues such as end-of-work routines, social events, stores, anticipated celebrations, and learned expectations of relaxation or relief. People may experience craving in response to stress, positive mood, or the sight and smell of alcohol. The clinical implications depend on drinking history and severity, medical risk, treatment goals, and whether withdrawal is present. NIAAA recognizes cue identification and coping skills as components of evidence-based behavioral care and notes that naltrexone can reduce urges to drink, while acamprosate can support abstinence by reducing certain post-cessation symptoms. NIAAA, Treatment for Alcohol Problems.

Craving reduction is one possible treatment response, yet broader outcomes include heavy-drinking days, sustained abstinence or reduction goals where appropriate, health, social functioning, and treatment retention. Clinically significant physiological dependence requires additional safety assessment because alcohol withdrawal can progress to seizures and delirium. A person who drinks heavily and regularly should seek medical guidance before abruptly stopping; subjective craving severity cannot determine whether unsupervised withdrawal is safe.

Opioids: reward learning, withdrawal relief, and overdose risk

Opioid-related craving may reflect learned reward, anticipatory relief of withdrawal symptoms, contextual reminders, pain, stress, or multiple motives at once. The separation between craving and withdrawal is particularly important because effective medications for opioid use disorder can reduce withdrawal and craving while supporting longer-term treatment and survival. Methadone and buprenorphine are evidence-based medications; extended-release naltrexone is another option for appropriately selected patients after clinically suitable initiation conditions. Treatment choice is individualized and requires professional assessment. CDC, Opioid Use Disorder: Treating.

An intense urge can increase the likelihood of renewed exposure, and tolerance may be reduced after a period without opioids. This increases overdose danger when previously familiar amounts are taken, especially with potent illicitly manufactured opioids or combined sedatives. Naloxone can reverse opioid-induced respiratory depression, and emergency medical services are necessary when a person is unresponsive, breathing abnormally, or suspected of overdosing. A craving episode itself is not an overdose, and clinical safety messaging should preserve that distinction.

Nicotine: frequent environmental cues and short cycles

Nicotine craving can be linked to frequent, highly rehearsed routines: awakening, a break at work, driving, meals, drinking alcohol, social interaction, or handling a device. Nicotine withdrawal can increase irritability, restlessness, concentration difficulty, and desire to smoke or vape. The high frequency of daily cues may create many short opportunities for craving, which makes environmental restructuring and evidence-based cessation support clinically relevant. Nicotine replacement therapy, varenicline, and bupropion have established roles in smoking cessation for suitable patients, with selection based on individual health and access considerations.

Research involving tobacco has contributed heavily to momentary craving science, but its cue frequency and delivery characteristics should not be assumed to generalize directly to opioids, alcohol, cannabis, or stimulants. The relationship between self-reported urges and behavior depends on the substance, measurement window, setting, and level of dependence. Serre and colleagues, 2015.

Stimulants: salient cues, extended vulnerability, and psychiatric safety

Craving for cocaine or methamphetamine may be activated by drug-related cues, anticipated stimulation, particular companions, sexual situations, sleep disruption, or stressful periods. Some individuals experience episodic urges after an interval without use; others report more persistent preoccupation. Stimulant use can also produce acute cardiovascular toxicity, agitation, and psychotic symptoms, which require a different response from routine craving assessment. Chest pain, seizures, severe overheating, marked confusion, or severe agitation warrant urgent emergency evaluation. ASAM and AAAP, 2024.

The best-supported behavioral treatment for stimulant use disorder is contingency management, often combined with cognitive behavioral therapy or other psychosocial interventions. Its effectiveness is established for relevant use outcomes, whereas the degree to which an intervention directly suppresses every subjective craving is a separate question. This distinction matters when clinicians choose evidence-based treatment on the basis of functioning and substance use rather than an isolated urge score. ASAM and AAAP clinical guideline.

Cannabis and sedative substances

Cannabis-related cravings may involve familiar social settings, sleep expectations, stress-related coping, and conditioned sensory reminders. Withdrawal can include irritability, sleep disturbance, appetite changes, and restlessness, which can contribute to relief-oriented motives without being identical to craving. Current intervention research for cannabis use disorder relies primarily on psychosocial approaches, and patients require individualized assessment of co-occurring conditions and changing goals.

For benzodiazepines and related sedatives, a desire for the medication may coexist with physiological dependence, rebound symptoms, anxiety, or problematic use. Clinicians must distinguish treatment adherence, therapeutic benefit, withdrawal discomfort, and compulsive use. Abrupt cessation after sustained exposure can cause dangerous withdrawal, including seizures. Decisions about tapering or discontinuation require professional supervision. Craving terminology alone cannot determine either addiction status or a safe discontinuation strategy. ASAM benzodiazepine tapering guideline.

Craving Over Time: Intoxication, Abstinence, Remission, and Recovery

Early changes after reducing or stopping use

The first days or weeks after a change in use can involve withdrawal, shifting routine, disrupted sleep, stress, and exposure to cues that were previously paired with consumption. The duration and medical seriousness vary widely among substances. Craving may intensify temporarily, fluctuate, or decrease as new habits and treatment take effect. Withdrawal management focuses on immediate physiological safety; long-term care also addresses the learned, emotional, cognitive, and contextual pathways that contribute to continued use.

Because craving and withdrawal are different constructs, the disappearance of withdrawal signs does not imply that the motivational or behavioral risk has ended. Similarly, continuing urges after medically supervised withdrawal do not necessarily indicate that withdrawal treatment was ineffective. Treatment planning integrates medical management with the person's broader recovery goals, evidence-based behavioral interventions, social needs, and ongoing follow-up.

Cue sensitivity during remission

Remission in diagnostic systems refers to the course of the disorder according to defined criteria. Recovery is a broader, multidimensional process encompassing health, functioning, relationships, and personally meaningful outcomes. Craving can appear during periods when other disorder criteria are absent or much improved. This is particularly important because a strong cue response can sometimes remain after a substantial period of reduced or no use, while learned alternative responses and supports may also become stronger over time.

A person in recovery may encounter previously associated cues without using, may experience episodic craving with no behavioral consequences, or may benefit from additional treatment when urges become disruptive. The frequency and consequences of urges are more useful when interpreted longitudinally than when used as a single dividing line between 'successful' and 'unsuccessful' recovery. Recovery support should allow people to discuss cravings openly without equating their presence with moral failure or inevitable recurrence.

Recurrence and relapse language

The words lapse, recurrence, and relapse are used differently across research and clinical settings. A return to substance use may involve one episode, a brief period, or the reestablishment of a sustained harmful pattern. Definitions should specify the actual measured event. Craving often precedes some episodes, but the episode also reflects opportunities, support, drug supply, treatment continuity, and wider circumstances. Labeling any craving as relapse confuses motivation with behavior; labeling every single use episode as complete collapse obscures clinically useful differences in severity and response.

The strongest course-oriented response after renewed use is reassessment: what substance was used, whether intoxication or overdose risk exists, what changed in exposure or support, and which treatment options remain accessible. A person who has used opioids after a period without use may have heightened overdose vulnerability. Effective recovery care emphasizes rapid, nonstigmatizing re-engagement and appropriate medical safety assessment, regardless of which term is used for the event.

What Can Reduce Craving or Change the Response to It?

Behavioral approaches and cognitive behavioral therapy

Cognitive behavioral approaches examine learned associations, anticipatory beliefs, coping behavior, daily routines, and the relationship between emotional states and substance use. Patients may work with clinicians to notice early cues, test beliefs about immediate relief, increase access to rewarding alternatives, and rehearse responses compatible with treatment goals. These approaches target patterns of behavior and risk broadly; reductions in a particular craving scale represent one potential mechanism or outcome. Treatment effectiveness should be judged by clinically meaningful endpoints such as substance use, retention, safety, and functioning, not only by laboratory reduction in cue response. NIAAA, Treatment for Alcohol Problems.

When a craving arises, an individual can discuss with their clinician whether pausing, observing its changing intensity, changing location, contacting support, engaging a previously planned activity, or creating distance from readily available substances fits their goals and medical circumstances. Such responses are examples of psychosocial strategies, not replacements for medication, urgent evaluation, or specialized treatment when those are indicated. The separately owned article on managing cravings during recovery can examine intervention protocols in depth; the scientific question here is how learned cue responses become more flexible.

Mindfulness-based approaches and urge surfing

Mindfulness-based interventions encourage awareness of current sensations, thoughts, and affect without an automatic behavioral response. The technique often called urge surfing invites observation of a craving's changing sensations and intensity while refraining from immediate action. Its therapeutic rationale is to create space between an urge and a learned response. The clinical evidence is mixed by study design and comparator. A meta-analysis of nine randomized trials involving 901 participants found low-quality evidence and no statistically significant difference from comparator interventions on relapse and frequency of use. Grant and colleagues, 2017.

A later systematic review of mindfulness-based relapse prevention reported favorable findings in several substance-use and mental-health outcomes across 13 studies, although program formats and co-interventions differed and settings were not widely evaluated. A 2026 umbrella review found preliminary positive signals for craving and relapse, while emphasizing heterogeneity and study-quality limits. These syntheses are compatible with cautious clinical use as an adjunct tailored to patient preferences, while leaving comparative effectiveness and durability of benefit as ongoing research questions. Ramadas and colleagues, 2021; Bakhtiarvand and Abedi, 2026.

Cue exposure and extinction-based interventions

Cue exposure therapy attempts to alter learned responses through repeated encounters with cues under controlled conditions without the usual reinforcing substance-use outcome. A 2025 qualitative systematic review examined 44 controlled studies across substances, including technology-assisted formats. The literature showed some favorable findings for craving and consumption, but findings differed across comparisons and interventions, and the review identified substantial heterogeneity and risk of bias. Only two studies were rated low risk of bias; a higher proportion of favorable technology-assisted results cannot establish superiority without strong direct comparisons. Thaysen-Petersen and colleagues, 2025.

Cue exposure should therefore be described as an intervention with an evolving and qualified evidence base, particularly for virtual-reality delivery and generalization beyond the clinic. Presenting it as a universally established standalone cure would exceed the evidence. It also requires trained implementation and consideration of the individual's substance, stability, risks, and treatment setting; unsupervised deliberate exposure to potent drug cues can increase distress or risk in some circumstances.

Medications and substance-specific treatment

Medication effects vary by disorder and mechanism. For alcohol use disorder, naltrexone can reduce urges or rewarding effects, while acamprosate supports abstinence for some patients. For opioid use disorder, methadone and buprenorphine reduce withdrawal and craving and are associated with major clinical benefits when appropriately delivered. Nicotine cessation pharmacotherapies improve quitting outcomes. These are separate evidence-based treatments with different indications; none should be treated as a generic medication for all cravings. NIAAA treatment guide; CDC opioid treatment guidance.

Medication selection also depends on interactions, medical and psychiatric history, pregnancy, prior treatment response, patient preference, and safety. A subjective improvement in craving is valuable when it coincides with reduced harm and improved functioning, but the absence of complete craving elimination does not prove treatment failure. Medication-based care and behavioral or social support can address different parts of the clinical problem. Acute detoxification or withdrawal management by itself does not constitute comprehensive, continuing treatment for substance use disorder.

Social connection and access to alternative rewards

Housing stability, relationships, work, recreation, predictable routines, and opportunities to experience rewarding activities outside substance use may influence cue exposure, availability, stress, and motivation. Social support can also create opportunities to seek care before a high-risk situation becomes acute. The scientific literature increasingly examines how non-drug rewards might compete with drug-related motivation, but mechanistic claims about exactly how such rewards modify sensitization remain preliminary. Review of natural rewards and incentive sensitization, 2026.

The practical implication is to consider the entire environment in which craving occurs. A person cannot always remove a trigger, avoid a neighborhood, leave unsafe housing, or access treatment without logistical support. Clinical plans become more credible when they account for transportation, cost, caregiving, employment, stigma, and relationships alongside psychological skills.

Safety, Vulnerability, and Clinical Decision-Making

Acute medical emergencies are a different problem from craving

Craving warrants assessment and support; an overdose or severe withdrawal can require immediate emergency care. Signs of possible opioid overdose include unresponsiveness, slowed or absent breathing, and other signs of respiratory depression. Naloxone should be administered when available according to local guidance, and emergency medical services should be contacted immediately. Suspected severe alcohol or benzodiazepine withdrawal, including seizures, hallucinations, pronounced confusion, or delirium, requires urgent medical evaluation. Stimulant exposure accompanied by chest pain, seizure, severe agitation, or dangerous hyperthermia is another emergency. CDC opioid guidance; ASAM and AAAP, 2024.

A person who is physiologically dependent on alcohol or benzodiazepines may face serious medical danger from abrupt cessation. A craving-focused discussion must never be turned into a home detoxification or rapid-taper plan. Anyone with substantial or prolonged exposure should discuss changes with an appropriately qualified clinician. Acute suicidality, threatening psychosis, severe intoxication, or inability to remain safe also calls for immediate professional or emergency assistance rather than self-management of urges.

Adolescents, pregnancy, older adults, and co-occurring disorders

Developmental stage, medical conditions, trauma history, neurocognitive changes, and concurrent treatment affect the meaning and management of craving. Adolescents may face concentrated peer exposure and evolving self-regulation skills; pregnancy requires substance-specific evaluation and coordinated perinatal care; older adults may have polypharmacy, mobility, or cognitive vulnerabilities. A person with anxiety, depression, psychosis, chronic pain, or post-traumatic stress may report overlapping internal states that require an integrated assessment rather than a single-mechanism explanation.

Clinical care should therefore distinguish observable symptom patterns from diagnoses and tailor its discussion to medical risks and access needs. Overgeneralizing results from samples of adult tobacco smokers or alcohol treatment participants to every population would be scientifically unwarranted. Research samples frequently exclude severe psychiatric illness or complex medical conditions, limiting generalizability. Thaysen-Petersen and colleagues, 2025.

Poly-substance exposure and interaction risk

Craving can concern more than one substance, and triggers may activate linked routines involving alcohol, nicotine, opioids, stimulants, or sedatives. A person may report a desire for alcohol that usually occurs alongside smoking, or use a sedative in the context of stimulant-related insomnia. The resulting risks extend beyond any one craving score. Combined central nervous system depressants can amplify respiratory suppression, and exposure to an illicit supply can involve substances a person did not intend to take.

Assessment should identify all substances, relevant prescribed medications, recent changes in use, and current physical symptoms. Plans built around one trigger or substance can miss significant dangers when use is combined. Clinical evaluation and harm reduction should be anchored in actual exposure and safety, with confidentiality and nonstigmatizing language supporting accurate disclosure.

Research Limitations and Unresolved Questions

Measurement and causal inference

Craving research employs self-report, laboratory cues, physiological reactions, brain imaging, behavioral tasks, and momentary assessments. These approaches capture overlapping but distinct phenomena, and their correlations are rarely perfect. People may be reluctant to disclose urges or may experience them without words that map neatly onto a questionnaire. Objective physiological or neural signals also lack a unique one-to-one relationship with consciously experienced craving. A strong experimental response may not predict an individual's next-day behavior, and a weak response in a controlled setting may coexist with substantial real-world risk.

Future-oriented conclusions require attention to measurement validity, timing, participant selection, confounding, and the outcome under study. The large prospective meta-analysis provides robust evidence of an association between cue and craving indicators and subsequent use. It cannot, by itself, establish the effect of eliminating the urge through treatment. That intervention question requires appropriately designed comparative trials with clinically meaningful follow-up. Vafaie and Kober, 2022.

Heterogeneity across substances and populations

Alcohol, nicotine, cannabis, opioids, stimulants, and sedatives differ in pharmacology, withdrawal patterns, acute safety risks, cue frequency, and treatment availability. Studies also differ in diagnostic severity, current treatment status, age, gender distribution, living circumstances, abstinence duration, and comorbidity. A result established for laboratory smoking cues in adults cannot automatically settle the same question in a pregnant patient with opioid use disorder, or a person with severe mental illness and unstable housing.

Evidence syntheses can summarize common patterns while concealing meaningful variation. Researchers and clinicians should distinguish cross-substance mechanisms from substance-specific treatment claims, and should state when evidence comes mostly from convenience samples, short follow-up, or participants without complex medical conditions.

Why reducing an urge is not the only relevant endpoint

Lower craving may be meaningful to patients because it reduces distress, preoccupation, or interference with daily life. Yet treatment effectiveness also depends on overdose prevention, reduced substance-related harm, physical and mental health, sustained care engagement, quality of life, and functional recovery. An intervention might help people respond differently to urges without consistently eliminating them. Another intervention could reduce a craving score over a short session without producing durable improvement in use or health outcomes. Separating symptom measures, mechanisms, and clinical endpoints yields clearer conclusions.

Evidence currently supports clinically meaningful treatment models combining substance-specific medications where established, behavioral intervention, and sustained recovery support, while the effectiveness of a particular craving-focused technique depends on population, comparator, and outcome. Cue exposure and mindfulness programs illustrate why promising changes in subjective urge require evaluation against long-term substance use and functioning. Grant and colleagues, 2017; Thaysen-Petersen and colleagues, 2025.

Frequently Asked Questions About Cravings

Can someone have a craving without having addiction?

Yes. The experience of a strong desire to use a substance can occur without sufficient symptoms for a substance use disorder diagnosis. Craving is one DSM-5-TR criterion among several, and clinicians assess the whole pattern of use, impairment, risks, and functioning. The presence of craving may still justify discussing risky use or access to support, especially if it becomes persistent or distressing. DSM-5-TR diagnostic summary.

Why can a cue provoke craving after months or years?

Substance-related associative memories and motivational learning can remain responsive to particular contexts, even after substantial improvement in use or functioning. A cue can regain significance when combined with stress, renewed availability, or a familiar setting. The recurrence of an urge does not establish that previous recovery has disappeared, and a person's capacity to respond to cues may change through treatment and new experience. Robinson and Berridge, 2025.

Are cravings always stronger during withdrawal?

No. Withdrawal and craving can overlap, but their intensity and timing vary independently. Withdrawal involves substance-specific physiological and psychological changes, while craving concerns motivation to use. Cue-triggered urges can occur outside acute withdrawal, and significant withdrawal may require medical care regardless of the reported craving intensity. Alcohol and benzodiazepine withdrawal in particular may be medically dangerous.

Does every strong craving lead to substance use?

No. Prospective studies identify elevated risk on average, while individuals often experience urges without use. Opportunity, social support, treatment, habits, and competing goals influence outcomes. The presence of craving warrants thoughtful assessment and, when needed, adjustment of treatment; it is neither a behavioral act nor a certain prediction. Vafaie and Kober, 2022.

Is the goal of treatment to eliminate every craving?

Treatment aims at safer behavior, better health, reduced harm, and improved functioning in accordance with individual clinical needs and goals. Some treatments reduce craving directly; others help people respond to urges differently or address withdrawal, access, behavior, and social conditions. Continued occasional urges may coexist with successful recovery. Clinical decisions should not depend on a craving score alone. NIAAA treatment guidance.

Can mindfulness or virtual reality erase conditioned cues?

Current evidence supports investigating these approaches but does not demonstrate reliable erasure of learned associations. Mindfulness-based relapse prevention shows heterogeneous outcomes across reviews, and controlled cue exposure studies have substantial design and bias limitations, including for virtual-reality delivery. When used, such approaches belong in an individualized care plan and should be evaluated against long-term clinical outcomes. Thaysen-Petersen and colleagues, 2025; Grant and colleagues, 2017.

Scientific Synthesis

Craving in addiction is best understood as a variable motivational response arising from learned cues, expected rewards or relief, attention, internal states, and opportunities for action. Its clinical significance lies in how these processes interact with substance use and recovery over time. DSM-5-TR recognizes craving within a broader disorder framework, and prospective research supports its role as a meaningful indicator of future use. The relationship remains probabilistic: an urge can be intense without substance use, and substance use can occur with little consciously reported craving. Scientific models of incentive motivation, habit learning, negative reinforcement, and executive control clarify different parts of this pattern without reducing its social and clinical complexity to a single mechanism. Hasin and colleagues, 2013; Vafaie and Kober, 2022; Robinson and Berridge, 2025.

For clinical care, the practical priorities are to identify meaningful triggers, assess the person's complete substance-use and safety context, offer effective substance-specific treatment, and understand craving as one dimension of changing risk and functioning. Evidence-based care can reduce harms and improve recovery without promising that every conditioned response will vanish. The most useful scientific account connects subjective experience to behavior, clinical assessment to treatment, and individual coping to the environments in which choices and opportunities actually occur.

Related Articles

Cluster Substance Use Disorders and Addiction Recovery — the central scientific chapter on diagnosis, mechanisms, treatment, harm reduction, and recovery.

Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity — how anxiety and substance-related effects influence one another.

Neuroticism and Addiction: Substance Use, Negative Affect, and Risk — personality-related negative affect and patterns of substance-related vulnerability.

Substance-Induced Psychosis: Causes, Symptoms, and Treatment — distinct psychiatric assessment and safety concerns in substance-related psychosis.

Benzodiazepines for Anxiety: Benefits, Risks, Dependence, and Clinical Caution — therapeutic use, physical dependence, and clinical safety considerations.

Stress and Addiction: Coping, Negative Reinforcement, and Relapse — stress systems, coping behavior, negative reinforcement, and recurrence of use.

How to Manage Cravings During Addiction Recovery: Evidence-Based Skills — coping with conditioned craving and evidence-supported self-management skills.

Relapse in Addiction Recovery: Warning Signs, Risk, and Response — recurrence of substance use, predictors, response, and ongoing care planning.

References

American Society of Addiction Medicine. (2025). Joint clinical practice guideline on benzodiazepine tapering. Official guideline.

American Society of Addiction Medicine and American Academy of Addiction Psychiatry. (2024). The ASAM/AAAP clinical practice guideline on the management of stimulant use disorder. Journal of Addiction Medicine; full text.

Bakhtiarvand, P. A., and Abedi, M. R. (2026). How effective are mindfulness-based interventions for the treatment of substance use disorders, relapse prevention, and craving? An umbrella review. Substance Use and Misuse. DOI: 10.1080/10826084.2026.2699442.

Centers for Disease Control and Prevention. (2024). Opioid use disorder: Treating. Official CDC clinical guidance.

Grant, S., and colleagues. (2017). Mindfulness-based relapse prevention for substance use disorders: A systematic review and meta-analysis. Journal of Addiction Medicine. DOI: 10.1097/ADM.0000000000000338.

Hasin, D. S., O'Brien, C. P., Auriacombe, M., and colleagues. (2013). DSM-5 criteria for substance use disorders: Recommendations and rationale. American Journal of Psychiatry, 170, 834–851. Full text.

Koob, G. F., and Volkow, N. D. (2016). Neurobiology of addiction: A neurocircuitry analysis. The Lancet Psychiatry, 3, 760–773. DOI: 10.1016/S2215-0366(16)00104-8.

National Institute on Alcohol Abuse and Alcoholism. (n.d.). How to stop alcohol cravings. Rethinking Drinking. Official resource.

National Institute on Alcohol Abuse and Alcoholism. (n.d.). Treatment for alcohol problems: Finding and getting help. Official NIAAA guidance.

National Institute on Drug Abuse. (n.d.). Drugs, brains, and behavior: The science of addiction. Official NIDA publication.

Ramadas, E., and colleagues. (2021). Effectiveness of mindfulness-based relapse prevention in individuals with substance use disorders: A systematic review. Behavioral Sciences, 11, 133. DOI: 10.3390/bs11100133.

Robinson, T. E., and Berridge, K. C. (2025). The incentive-sensitization theory of addiction 30 years on. Annual Review of Psychology, 76, 29–58. DOI: 10.1146/annurev-psych-011624-024031.

Schacht, J. P., Anton, R. F., and Myrick, H. (2013). Functional neuroimaging studies of alcohol cue reactivity: A quantitative meta-analysis and systematic review. Addiction Biology, 18, 121–133. DOI: 10.1111/j.1369-1600.2012.00464.x.

Serre, F., Fatseas, M., Swendsen, J., and Auriacombe, M. (2015). Ecological momentary assessment in the investigation of craving and substance use in daily life: A systematic review. Drug and Alcohol Dependence, 148, 1–20. DOI: 10.1016/j.drugalcdep.2014.12.024.

Thaysen-Petersen, D., Hammerum, S. K., Düring, S. W., and colleagues. (2025). The efficacy of conventional and technology-assisted cue exposure therapy for treating substance use disorders: A qualitative systematic review. Frontiers in Psychiatry, 16, 1544763. DOI: 10.3389/fpsyt.2025.1544763.

Vafaie, N., and Kober, H. (2022). Association of drug cues and craving with drug use and relapse: A systematic review and meta-analysis. JAMA Psychiatry, 79, 641–650. PubMed PMID: 35648415.